Figure 5
Figure 5. Survival after relapse in patients randomized to gemtuzumab ozogamicin (GO) versus no further therapy (no GO).

Survival after relapse in patients randomized to gemtuzumab ozogamicin (GO) versus no further therapy (no GO).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal